Laiginhas R, et al. - The goal of this paper was to assess the functional and anatomical outcomes after aflibercept in patients with diabetic macular edema (DME) with poor response to bevacizumab. Functional and anatomical improvements were yielded due to the conversion to aflibercept for persistent DME. Such outcomes were not affected by previous bevacizumab exposure. It was deduced that pre-switch central macular thickness (CMT) served as a predictor of anatomical changes after aflibercept.